AstraZeneca betters estimates amid strong sales, Covid-19 vaccine hopes

Britain's AstraZeneca bettered second-quarter sales and profit estimates on Thursday, thanks to strong sales during the lockdowns from the drugmaker's diverse product line-up, which now includes a front-running coronavirus vaccine candidate. Optimism over its Covid-19 vaccine has fuelled what was already a strong year for the company as it also stuck by its 2020 outlook.

AstraZeneca has gained from changes wrought by Chief Executive Pascal Soriot's focus on products and bets on newer medicines. The company reiterated that.

This article is no longer available in our repository.

There could be multiple reasons for this.